10-Q: KALA BIO Faces Delisting, Foreclosure After Trial Failure

KALA BIO, Inc. announced the failure of its key clinical trial, leading to a default on its primary loan, asset foreclosure by Oxford Finance, significant workforce reductions, and substantial doubt about its ability to continue as a going concern.

Summary

• The CHASE Phase 2b clinical trial for KPI-012 in persistent corneal epithelial defects (PCED) failed to meet its primary and key secondary endpoints.
• Development of KPI-012 and the MSC-S platform has ceased, leading to a 51% workforce reduction (19 employees) in September 2025, with further terminations in October 2025.
• Oxford Finance LLC issued a default notice on September 29, 2025, accelerating $29.1 million in obligations due to a 'Material Adverse Change'.
• Oxford Finance swept substantially all cash resources on October 18, 2025, and intends to foreclose on remaining assets, with approximately $9.6 million still owed after the sweep.
• A $375,000 convertible loan was secured from an individual investor on November 9, 2025, specifically to fund strategic option exploration and SEC filing preparation.
• There is substantial doubt about the ability to continue as a going concern, and strategic options, including sale, license, merger, or bankruptcy, are being explored.
• Nasdaq issued a deficiency notice on November 10, 2025, for non-compliance with the $35 million minimum market value of listed securities requirement, with a compliance date of May 11, 2026.
• Net loss for the three months ended September 30, 2025, was $7.564 million, compared to $8.950 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $27.666 million, compared to $30.336 million for the same period in 2024.
• Cash and cash equivalents decreased from $51.181 million at December 31, 2024, to $21.096 million at September 30, 2025.

Sentiment

Score: 1

Explanation: The company is in severe financial distress, marked by the failure of its lead clinical asset, cessation of all R&D, mass layoffs, default on its primary debt, asset foreclosure by its lender, and a Nasdaq delisting notice. Management has expressed substantial doubt about the company's ability to continue as a going concern, with bankruptcy being a stated possibility and little to no recovery expected for stockholders in such an event. The small convertible loan is a temporary measure to explore strategic options, not a solution to its fundamental problems.

Positives

• A gain on fair value remeasurement of contingent consideration of $4.833 million for the three months and $4.659 million for the nine months ended September 30, 2025, was recognized due to the reduced likelihood of future payments after ceasing KPI-012 development.
• A $375,000 convertible loan was secured to fund strategic option exploration and SEC filing preparation, providing a temporary lifeline.
• Net loss decreased for both the three-month ($7.564 million vs $8.950 million) and nine-month ($27.666 million vs $30.336 million) periods compared to the prior year, primarily due to the gain on contingent consideration and reduced R&D post-trial failure.

Negatives

• The CHASE Phase 2b clinical trial for KPI-012 failed to meet its primary and key secondary efficacy endpoints, showing no meaningful difference between treatment and placebo arms.
• Development of KPI-012 and the entire MSC-S platform has been ceased.
• A significant workforce reduction of 51% (19 employees) occurred in September 2025, followed by the termination of all remaining employees not deemed necessary by Oxford Finance on October 19, 2025.
• Defaulted on the Loan Agreement with Oxford Finance LLC, leading to the acceleration of $29.1 million in debt obligations.
• Oxford Finance swept substantially all cash resources on October 18, 2025, and intends to foreclose on remaining assets.
• Management has concluded there is substantial doubt about the ability to continue as a going concern.
• Received a Nasdaq deficiency notice on November 10, 2025, for not meeting the $35 million minimum market value of listed securities requirement.
• Will not receive the remaining $0.6 million disbursement from the California Institute for Regenerative Medicine (CIRM) Award due to the cessation of KPI-012 development.
• Cash and cash equivalents significantly decreased from $51.181 million at December 31, 2024, to $21.096 million at September 30, 2025, and further reduced by Oxford's sweep.
• An impairment of right-of-use assets of $1.411 million was recorded due to the Menlo Park lease no longer providing future benefits.
• Stockholders' equity moved from a positive $12.332 million at December 31, 2024, to a deficit of $(8.665) million at September 30, 2025.
• Accumulated deficit increased to $695.586 million as of September 30, 2025.

Risks

• Exploration and pursuit of strategic options and additional financing may not be successful, potentially leading to no value realization for the company or stockholders.
• If no transaction or financing occurs, Oxford Finance is expected to resume foreclosure efforts on assets.
• The board of directors may elect to commence bankruptcy or insolvency proceedings, making it highly unlikely that cash will be available for distribution to stockholders.
• Substantial dependence on remaining employees and consultants to facilitate strategic options and financing, with the risk of losing these individuals.
• Potential for securities class action litigation or SEC investigations, which could divert management's attention and harm remaining cash resources.
• Failure to comply with Nasdaq listing requirements (e.g., Minimum MVLS Requirement) could result in delisting, reducing stock liquidity and ability to access capital markets.
• Delisting from Nasdaq or transfer to a less restrictive exchange are additional events of default under the Loan Agreement with Oxford Finance.
• The company is insolvent, has no cash or liquid assets (other than the convertible loan), and has illiquid asset value that is low or indeterminable.
• Existing obligations to secured and unsecured creditors exceed $9.8 million (secured) and $8.3 million (unsecured) prior to the convertible loan agreement date.
• Any financial obligations under the convertible loan agreement, including repayment of the loan amount or indemnification, may never be paid.
• Uncertainty regarding the timing or amount of potential milestone payments from Alcon (up to $325 million).
• Inability to achieve or maintain profitability, with significant expenses and operating losses expected if R&D activities were to resume.
• Raising additional capital through equity or convertible debt securities will result in ownership dilution for existing stockholders.
• Debt financing and preferred equity financing, if available, may involve restrictive covenants limiting future actions.
• Inability to raise additional funds could lead to delays, limits, reductions, or termination of product development/commercialization efforts, or cessation of operations.
• Utilization of net operating loss carryforwards is subject to an annual limitation of $222,000 due to prior ownership changes.

Future Outlook

The company expects its cash and cash equivalents as of September 30, 2025, were insufficient to fund operations through November 2025. There is substantial doubt about its ability to continue as a going concern. Subject to securing additional financing, the company plans to continue SEC filing obligations and explore strategic options, including asset monetization, seeking additional funding, or resuming R&D activities. Any resumption of R&D would depend on a strategic transaction or significant additional funding. If R&D resumes, the focus would be on preclinical testing for KPI-012 and KPI-014 for ocular diseases. If no transaction or financing occurs, Oxford Finance is expected to resume foreclosure. The board may initiate bankruptcy proceedings, in which case it is highly unlikely stockholders would receive any distribution.

Management Comments

• We determined to cease development of KPI-012 and our MSC-S platform and to take steps to preserve cash as the Company explores its strategic options.
• It is highly unlikely that there will be cash available for distribution to our stockholders in such event [bankruptcy] and the Company cannot assure you as to the amount or timing of distributions, if any.
• Mr. Bazemore continues to serve as our principal executive officer, pursuant to the terms of a consulting agreement.

Industry Context

The biopharmaceutical industry, particularly in rare and severe diseases, is characterized by high R&D costs, long development timelines, and significant clinical trial risks. KALA BIO's situation highlights the extreme financial vulnerability of small biotech companies when a lead product candidate fails in late-stage trials. The immediate cessation of development, mass layoffs, and default on debt are common, albeit severe, consequences in this high-risk, high-reward sector. The struggle to secure financing and the threat of delisting are also typical challenges for companies facing such setbacks, especially without revenue-generating products.

Comparison to Industry Standards

• Clinical Trial Failure: The failure of a Phase 2b trial is a significant setback, common in drug development, but particularly devastating for a company like KALA BIO that had pivoted its entire strategy around KPI-012 after selling its commercial assets. This outcome contrasts sharply with companies like Aerie Pharmaceuticals (Rhopressa) or Ocular Therapeutix (Dextenza) that have successfully navigated clinical development and commercialization in ophthalmology.
• Financial Distress: The rapid depletion of cash, default on a major loan, and subsequent asset sweep by a lender (Oxford Finance) are indicative of severe financial distress, often leading to bankruptcy or forced asset sales. This is a stark contrast to well-capitalized biotechs or those with approved products generating revenue.
• Workforce Reduction: A 51% workforce reduction followed by termination of nearly all remaining employees is an extreme measure, signaling a near-complete shutdown of operations, far beyond typical restructuring seen in the industry.
• Nasdaq Delisting: Receiving a Nasdaq deficiency notice for market value is a common issue for struggling small-cap biotechs, but combined with the other factors, it underscores the company's precarious position. Many companies, like Sorrento Therapeutics, have faced delisting threats or actual delisting due to financial issues or low stock prices.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently subject to any material legal proceedings.

Related Party Transactions

• Entered into a Convertible Loan Agreement on November 9, 2025, with an individual investor, Mr. David Lazar, for an aggregate amount of up to $375,000.

Stakeholder Impact

• Shareholders: Highly likely to lose all or a significant portion of their investment, especially in the event of bankruptcy. Significant dilution risk from potential future equity raises or convertible loan conversion. Share price negatively impacted by trial failure, loan default, and delisting threat.
• Employees: Significant negative impact due to mass layoffs (51% initially, then nearly all remaining employees terminated).
• Creditors (Oxford Finance LLC): Initiated default proceedings, accelerated debt, and swept cash, indicating an attempt to recover their investment. Approximately $9.6 million still owed after the sweep.
• Creditors (Individual Lender David Lazar): Provided a convertible loan, but repayment is uncertain given the company's financial state. Has conversion rights into equity.
• Combangio Equityholders: Future milestone and royalty payments are highly unlikely due to the cessation of KPI-012 development.
• California Institute for Regenerative Medicine (CIRM): Will not disburse the remaining $0.6 million of the grant due to the cessation of KPI-012 development.

Next Steps

• Continue to comply with filing obligations under the Securities Exchange Act of 1934.
• Resume exploration of strategic options, which may include a sale, license, merger, or other monetization of remaining assets.
• Seek additional financing.
• Subject to additional funding, resume certain research and development activities, focusing on preclinical testing for KPI-012 and KPI-014 for ocular diseases.
• Monitor the market value of listed securities and consider options to regain Nasdaq compliance.
• Negotiate and finalize a potential additional financing transaction with the individual lender or another third-party.
• Prepare for potential resumption of Oxford Finance's foreclosure efforts if no transaction or financing occurs.
• The board of directors may decide to commence bankruptcy or insolvency proceedings.

Key Dates

Recommendation

KALA BIO is in an extremely precarious financial and operational state. The failure of its lead clinical trial (KPI-012), the subsequent cessation of all R&D, and the mass termination of employees signal the end of its core business strategy. The default on its primary loan with Oxford Finance, leading to asset foreclosure and cash sweep, leaves the company with minimal resources and substantial debt. The Nasdaq delisting notice further compounds the negative outlook, severely limiting future capital access and liquidity. Management explicitly states 'substantial doubt about its ability to continue as a going concern' and acknowledges that bankruptcy is a possibility with 'highly unlikely' cash available for stockholders. While a small convertible loan provides a temporary reprieve for exploring strategic options, it does not address the fundamental issues. Given the high probability of significant or total loss of investment, a strong sell recommendation is warranted.

Keywords

Biopharmaceutical, Clinical trial failure, KPI-012, Persistent corneal epithelial defect, MSC-S platform, Workforce reduction, Loan default, Oxford Finance, Foreclosure, Going concern, Nasdaq delisting, Convertible loan, Strategic options, Ocular diseases, Biotech, Ophthalmology, Asset monetization, Bankruptcy